Trial Profile
The Effectiveness of Ranolazine in Reducing Cardiac Ischaemia Induced by Chronic Total Occlusions of Coronary Arteries
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary)
- Indications Ischaemia
- Focus Therapeutic Use
- 03 Jun 2017 Status changed from recruiting to withdrawn prior to enrolment.
- 13 May 2016 Status changed from not yet recruiting to recruiting.
- 25 Apr 2015 New trial record